![]() | ![]() |
Lantern Pharma Gets Regulatory Approval to Expand Harmonic Clinical Trial for NSCLC
Lantern Pharma Inc. has secured regulatory approval to expand its Harmonic trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer (NSCLC) in never-smokers in both Japan and Taiwan.
NSCLC | 23/04/2024 | By Aishwarya
Genentech Receives Approval from FDA for Alecensa
Genentech, a member of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
NSCLC | 22/04/2024 | By Aishwarya | 219
BerGenBio Begins Phase 2a in First Line NSCLC Patients with STK11m
BerGenBio ASA has initiated Phase 2a portion of the BGBC016 clinical study of its selective AXL inhibitor bemcentinib in combination with standard of care therapy in first-line Non-Small Cell Lung Cancer (NSCLC) patients
NSCLC | 21/03/2024 | By Manvi | 220
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy